Among the constituents a nicotine product is tested for, tobacco-specific nitrosamines (TSNAs) sit near the top of the safety list. They are potent carcinogens, they appear on the FDA’s harmful-and-potentially-harmful-constituents list, and their levels are a key differentiator between products and nicotine sources.
What TSNAs are
TSNAs are a family of nitrosamines formed from tobacco alkaloids during curing and processing. The most watched are NNN and NNK, alongside NAT and NAB. They are recognized carcinogens, which is why their control is a priority for tobacco-derived products.
Why the nicotine source matters
Because TSNAs come from tobacco, tobacco-derived nicotine can carry them, while synthetic nicotine is made without tobacco and typically contains far lower levels. This is a real, testable distinction, and one regulators now scrutinize regardless of source.
How TSNAs are tested
TSNAs are present at very low levels, so they demand sensitive, specific methods, typically LC-MS/MS, which can quantify individual nitrosamines down to trace concentrations. A method without that sensitivity cannot credibly report a TSNA result.
Limits and reporting
TSNA results are judged against limits appropriate to the product and market, and are a standard part of the harmful-constituent data expected in regulatory submissions. Individual nitrosamines should be reported separately, not as a single lumped figure.
Reading a TSNA result
Look for NNN and NNK reported individually by LC-MS/MS, with detection limits and the limits they are compared against. Given how low the safety thresholds are, the method’s sensitivity is as important as the number itself.
